Distinguishing between inflammatory bowel disease and low-grade intestinal lymphoma in cats is one of the most challenging diagnostic problems in feline medicine, with significant welfare implications for treatment and prognosis.
The IBD-lymphoma diagnostic challenge has direct welfare implications. Cats with small cell lymphoma who are treated as IBD may receive inadequate treatment that allows their cancer to progress, causing unnecessary deterioration. Conversely, cats with IBD treated with chemotherapy face medication side effects without benefit. The diagnostic process itself — requiring general anesthesia for biopsy, associated recovery, and the cost and delay of specialized laboratory testing — creates welfare costs that must be weighed against the significant benefit of accurate diagnosis and appropriate treatment. The welfare case for thorough investigation including biopsy is strong for cats showing inadequate response to initial treatment, as accurate diagnosis enables substantially better welfare outcomes through appropriate management of each condition.